Direct comparison of doses did not show evidence of dose dependence for blood pressure-lowering for any of the other thiazides for which RCT data were available : bendrofluazide , chlorthalidone , cyclopenthiazide , metolazone or indapamide .
This is based on an informal indirect comparison of results observed in other Cochrane review s on ACE inhibitors , ARBs and renin inhibitors compared with placebo , which used similar inclusion /exclusion criteria to the present review .Thiazides reduced potassium , increased uric acid and increased total cholesterol and triglycerides .
These effects were dose-related and were least for hydrochlorothiazide .
Chlorthalidone increased serum glucose but the evidence was unclear for other thiazides .
This systematic review shows that hydrochlorothiazide has a dose-related blood pressure-lowering effect .
Thiazides reduced potassium , increased uric acid and increased total cholesterol and triglycerides
BACKGROUND Hypertension is a modifiable cardiovascular risk factor .
Although it is established that low-dose thiazides reduce mortality as well as cardiovascular morbidity , the dose-related effect of thiazides in decreasing blood pressure has not been subject to a rigorous systematic review .
It is not known whether individual drugs within the thiazide diuretic class differ in their blood pressure-lowering effects and adverse effects .
OBJECTIVES To determine the dose-related decrease in systolic and /or diastolic blood pressure due to thiazide diuretics compared with placebo control in the treatment of patients with primary hypertension .
Secondary outcomes included the dose-related adverse events leading to patient withdrawal and adverse biochemical effects on serum potassium , uric acid , creatinine , glucose and lipids .
THE ANTIHYPERTENSIVE PROPERTIES OF THE ANGIOTENSIN‐CONVERTING ENZYME INHIBITOR MOEXIPRIL GIVEN ALONE OR IN COMBINATION WITH A LOW DOSE OF A DIURETIC
The antihypertensive characteristics of the angiotensin-converting enzyme inhibitor moexipril were evaluated in 413 patients with baseline sitting diastolic blood pressures between 95 and 114 mm Hg . The study was double blind , with patients r and omized to placebo or to differing doses of  moexipril alone or in combination with a low dose of hydrochlorothiazide . Compared with placebo , moexipril 3.75 mg daily was not different , but single daily doses of 7.5 , 15 , and 30 mg were significantly more effective ( as measured at trough , approximately 24 h after dosing ) in decreasing the diastolic blood pressuring during an 8-week treatment period . The dose – response relationship indicated that no additional blood-pressure-lowering effect occurred above 15 mg daily . Hydrochlorothiazide 12.5 mg was not significantly more effective than placebo , but the combinations of the diuretic with moexipril doses of 3.75 , 7.5 , and 15 mg all produced significant antihypertensive actions . Interestingly , the 3.75-mg moexipril-hydrochlorothiazide combination was equally as efficacious as the higher doses . The combinations were all more effective than their respective moexipril and hydrochlorothiazide monotherapies . There were no meaningful laboratory changes except for decreased potassium concentrations in the patients on diuretic alone ; this effect was attenuated in the low-dose moexipril combination . Only 14 of the 413 patients who entered the double-blind study period ( 3 % ) discontinued treatment because of adverse experiences . Thus , moexipril is a well-tolerated drug that has clear antihypertensive efficacy as a single agent in once-daily doses of 7.5–30 mg . When combined with hydrochlorothiazide 12.5 mg , it is effective in daily doses as low as 3.75 mg
Direct comparison of doses did not show evidence of dose dependence for blood pressure-lowering for any of the other thiazides for which RCT data were available : bendrofluazide , chlorthalidone , cyclopenthiazide , metolazone or indapamide .
This is based on an informal indirect comparison of results observed in other Cochrane review s on ACE inhibitors , ARBs and renin inhibitors compared with placebo , which used similar inclusion /exclusion criteria to the present review .Thiazides reduced potassium , increased uric acid and increased total cholesterol and triglycerides .
These effects were dose-related and were least for hydrochlorothiazide .
Chlorthalidone increased serum glucose but the evidence was unclear for other thiazides .
This systematic review shows that hydrochlorothiazide has a dose-related blood pressure-lowering effect .
Thiazides reduced potassium , increased uric acid and increased total cholesterol and triglycerides
BACKGROUND Hypertension is a modifiable cardiovascular risk factor .
Although it is established that low-dose thiazides reduce mortality as well as cardiovascular morbidity , the dose-related effect of thiazides in decreasing blood pressure has not been subject to a rigorous systematic review .
It is not known whether individual drugs within the thiazide diuretic class differ in their blood pressure-lowering effects and adverse effects .
OBJECTIVES To determine the dose-related decrease in systolic and /or diastolic blood pressure due to thiazide diuretics compared with placebo control in the treatment of patients with primary hypertension .
Secondary outcomes included the dose-related adverse events leading to patient withdrawal and adverse biochemical effects on serum potassium , uric acid , creatinine , glucose and lipids .